Evaluation of cancer screening services provided for people living with HIV in Botswana, 2022–2023
Health Promotion International · 2024
DOI: 10.1093/heapro/daae042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Promotion International, 2024. Verfasst von Anikie Mathoma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Research and Innovation, University of Botswana, Corner of Notwane and Mabuto Road, Plot 4775, Gaborone, Botswana. Hauptthemen laut MEDLINE: HIV Infections, Early Detection of Cancer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: University of KwaZulu Natal, University of Botswana.
Abstract (Originalsprache)
People living with human immunodeficiency virus (PLHIV) have an increased risk of cancers. Currently, Botswana has no screening guidelines for common cancers in PLHIV except cervical cancer. Also, the proportion of PLHIV who are screened for cancer is unknown. This study aimed to evaluate cancer screening services for PLHIV receiving care in the human immunodeficiency virus (HIV) clinics. Resources for cancer screening were assessed and medical records of adults initiating antiretroviral therapy (ART) from 2020 to 2021 in 20 high-volume HIV clinics in Gaborone and Francistown were reviewed. Questionnaires assessing knowledge and practices of cancer screening were administered to health workers. The majority of clinics had the required resources for cancer screening (specifically cervical cancer). Of the 62 health workers working at the HIV clinics, 57 (91.9%) completed the questionnaire: 35 (62.5%) nurses and 22 (37.5%) doctors. Only 26.3% of the health workers were trained in cervical cancer screening. Doctors were more likely to report practicing routine screening of other cancers (e.g. breast) (p = 0.003) while more nurses reported assessing patients for cancer history during follow-up visits (p = 0.036). Most health workers did not perform physical examinations to detect cancer at initial or follow-up visits. Of the 1000 records of PLHIV reviewed, 57.3% were females, and only 38% of these were screened for cervical cancer. Besides cervical cancer, almost all (97.8%) were not screened for any cancer at ART initiation and during follow-up. These findings highlight the need to improve cancer screening services of PLHIV in Botswana through the training of health workers, and the development and enhanced use of screening guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Research and Innovation, University of Botswana, Corner of Notwane and Mabuto Road, Plot 4775, Gaborone, Botswana.
- Discipline of Public Health Medicine, School of Nursing and Public Health, College of Health Sciences, University of KwaZulu-Natal, 236 George Campbell Building, King George V Avenue, Durban 4001, South Africa.
- Faculty of Medicine, UQ Centre for Clinical Research (UQCCR), University of Queensland, Brisbane, St Lucia QLD 4072, Australia.
- Centre for Tropical Medicine and Global Health, University of Oxford, New Richards Building, Roosevelt Dr, Headington, Oxford OX3 7LG, UK.
- Department of Health Metric Sciences, University of Washington, 3980 15th Ave NE, Seattle, WA 98195, USA.
ORCID-Profile: Anikie Mathoma
Förderung
- University of KwaZulu Natal
- University of Botswana
Zitieren
APA
Mathoma, A., Sartorius, B., & Mahomed, S. (2024). Evaluation of cancer screening services provided for people living with HIV in Botswana, 2022–2023. Health Promotion International. https://doi.org/10.1093/heapro/daae042
Vancouver
Mathoma A, Sartorius B, Mahomed S. Evaluation of cancer screening services provided for people living with HIV in Botswana, 2022–2023. Health Promotion International. 2024. doi:10.1093/heapro/daae042
BibTeX
@article{Mathoma2024,
author = {Mathoma, Anikie and Sartorius, Benn and Mahomed, Saajida},
title = {Evaluation of cancer screening services provided for people living with HIV in Botswana, 2022–2023},
journal = {Health Promotion International},
year = {2024},
doi = {10.1093/heapro/daae042}
}
EUVIMED